Highlights CASI Pharmaceuticals, Inc.

Equities

CASI

KYG1933S1012

Delayed Nasdaq Other stock markets 11:56:48 2024-05-01 am EDT			5-day change	1st Jan Change
2.37 ^USD	+0.68%		-2.87%	-66.90%

Mar. 28	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 05	Top Midday Gainers	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Rate Cut Uncertainty Pushes Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday	Mar. 05	MT
CASI Pharmaceuticals Report Positive Interim Phase 1 Data for BI-1206 in the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma in China	Mar. 05	CI
CASI Pharmaceuticals, Inc. and CASI Pharmaceuticals Co. Ltd Enter into Certain Agreement with Respect to the Renewal of the Exclusive Distribution Agreement with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd	Feb. 29	CI
Casi Pharmaceuticals Announces First Dose of Folotyn in China	Feb. 16	CI
CASI Pharmaceuticals, Inc. Enters into an Exclusive Distribution Agreement with China National Medicines Corporation Ltd	Dec. 08	CI
Earnings Flash (CASI) CASI PHARMACEUTICALS Posts Q3 Revenue $8.8M	Nov. 14	MT
CASI Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Earnings Flash (CASI) CASI PHARMACEUTICALS Posts Q2 Revenue $9.8M	23-08-11	MT
CASI Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
CASI Pharmaceuticals Acquires Intellectual Property Rights to Cleave Therapeutics' Drug Candidate CB-5339	23-07-20	MT
CASI Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-17	CI
Earnings Flash (CASI) CASI PHARMACEUTICALS Reports Q1 Revenue $8.3M	23-05-17	MT
CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-26	CI
Earnings Flash (CASI) CASI PHARMACEUTICALS Reports Q4 Revenue $43.1M	23-04-26	MT
North American Morning Briefing : Focus Turns to -2-	23-04-10	DJ
CASI Pharmaceuticals Completes Redomiciliation Merger	23-03-21	MT
CASI PHARMACEUTICALS COMPLETES REDOMICILIATION MERGER	23-03-21	PR
CASI, Cleave Say China Drug Regulator Approves Clinical Trial Application for CB-5339 in Patients With Multiple Myeloma	23-01-06	MT
CASI Pharmaceuticals, Inc. Announces Clinical Trial Application Approval for CB-5339 in Patients with Multiple Myeloma in China	23-01-06	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights CASI Pharmaceuticals, Inc.

Equities

CASI

KYG1933S1012

Highlights

Filters